Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Phase-Pfs'

Phase-Pfs published presentations and documents on DocSlides.

Median PFS: 2.6 months (95% CI, 1.7-3.5)
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Pay for Success: Innovative Financing to Improve Child Outcomes
Pay for Success: Innovative Financing to Improve Child Outcomes
by dominic513
Jennifer Tschantz; Early Childhood Research to Pra...
Matt Laurens, MD MPH on behalf of the PfSPZ Vaccine in Burkina Faso study team
Matt Laurens, MD MPH on behalf of the PfSPZ Vaccine in Burkina Faso study team
by amber
Division of Malaria Research. Institute for Global...
End-points utilized in breast cancer
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
by felicity
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
by willow
Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...
YIR On Demand Lung Benjamin Levy, MD 
YIR On Demand Lung Benjamin Levy, MD 
by jovita
Assistant Professor. Johns Hopkins School of Medic...
Summary 2011 Founded 2010
Summary 2011 Founded 2010
by eliza
in Houston. Vision: To be the leader in the develo...
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
by TravelingSoulmate
PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Update on Diagnosis and Treatments
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
2022 Spring Oncology Conference
2022 Spring Oncology Conference
by byrne
Evolving Treatment Strategies. for CLL/SLL and MCL...
Presentation
Presentation
by wang
pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...
Nouveautés dans le CBNPC métastatique
Nouveautés dans le CBNPC métastatique
by vizettan
Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...
Game Plan Trends in ovarian cancer
Game Plan Trends in ovarian cancer
by alexa-scheidler
Diagnostic work-up. Treatment. The most commonly ...
End-points utilized in
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
Pharmaceuticals Procurement
Pharmaceuticals Procurement
by kittie-lecroy
and Supply Management:. The case of Ethiopia. Cam...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
PFSE & FMI Foundation
PFSE & FMI Foundation
by giovanna-bartolotta
Recipe Modification Partnership Update. February ...
Interpretation of the Great Plains Polygonal Fault
Interpretation of the Great Plains Polygonal Fault
by luanne-stotts
Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...
Applying “Pay for Success” Social Impact Finance to Ear
Applying “Pay for Success” Social Impact Finance to Ear
by luanne-stotts
Janis Dubno, Voices for Utah Children. Andrea Phi...
Thierry Le Chevalier, MD
Thierry Le Chevalier, MD
by aaron
How . d. o . International Regulatory Groups View...
Ray Jones
Ray Jones
by danika-pritchard
Director of Solutions Architecture and Field Enab...
Partnerships for Success
Partnerships for Success
by test
Creating Positive School Experiences And Develop...
Beyond Secret Handshakes:
Beyond Secret Handshakes:
by pasty-toler
Affiliation-Hiding Authenticated Key Exchange. Fr...
Snort for the Road
Snort for the Road
by kittie-lecroy
Warrior. Soapbox. What is Snort?. Snort is an ope...
Low cost firewall.
Low cost firewall.
by tatyana-admore
Using . pfSense. with SNORT for a firewall with ...
2014 Oklahoma Business Summit
2014 Oklahoma Business Summit
by marina-yarberry
Sarah Roberts, Inasmuch Foundation, Program Offic...
Thierry Le Chevalier, MD
Thierry Le Chevalier, MD
by yoshiko-marsland
How . d. o International Regulatory Groups View C...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
Treatment of
Treatment of
by natalia-silvester
Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
by zen
knowledge. ). Incorporate evidence-based research ...
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
by hadley
Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...
Ovarian Cancer: Standards of Care and New Opportunities
Ovarian Cancer: Standards of Care and New Opportunities
by majerepr
Robert L. Coleman, M.D.. Professor & . Vice Ch...